Strides Pharma Science Reports Steady Q1FY27 Performance; Revenue Grows 13% YoY, Ex-US Markets Boost Growth
Bangalore, India – Strides Pharma Science Ltd. today announced its consolidated financial results for the first quarter of the fiscal year 2027 (Q1FY27), which ended on June 30, 2026. The company reported stable performance with revenue increasing by 13% year-over-year (YoY).The company saw strong growth in its Ex-US markets, where revenue rose 17% YoY to ₹5,875m ($63m). Meanwhile, the US business remained steady at ₹6,282m, representing a 4% increase over the previous year. Total revenue reached ₹12,654m in Q1FY27.Earnings before interest, depreciation and amortization (EBITDA) grew by 5.4% YoY to ₹2,298m, achieving an EBITDA...